Last reviewed · How we verify

NCT07275203

Concordance of the Biology of Primary Breast Carcinoma and the Biology of Recurrence .

Not yet recruiting Last updated 29 January 2026
What this trial tests

trial testing No intervention in Breast Carcinoma in 200 participants. Not yet recruiting.

Timeline
1 March 2026
Primary endpoint
1 July 2026
1 October 2026

Quick facts

Lead sponsorSohag University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment200
Start date1 March 2026
Primary completion1 July 2026
Estimated completion1 October 2026

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

18 and older, any sex, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the study will discuss the concordance of the biology of primary breast carcinoma and the biology of recurrence. The study will be conducted at Department of Clinical Oncology, Sohag University Hospital and Sohag Cancer center, Sohag, Egypt. including Patients diagnosed and treated between 2015 and 2025 and Data will be collected from medical records, pathology reports, and radiology reports.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07275203.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing